Literature DB >> 28934433

Opposing Effects of Nitazoxanide on Murine and Human Norovirus.

Wen Dang1, Yuebang Yin1, Maikel P Peppelenbosch1, Qiuwei Pan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28934433     DOI： 10.1093/infdis/jix377

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  7 in total

1.  Nitazoxanide Inhibits Human Norovirus Replication and Synergizes with Ribavirin by Activation of Cellular Antiviral Response.

Authors:  Lei Xu; Buyun Ma; Wen Dang; Sunrui Chen; Yuebang Yin; Kyeong-Ok Chang; Maikel P Peppelenbosch; Qiuwei Pan
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

2.  Nitazoxanide protects cats from feline calicivirus infection and acts synergistically with mizoribine in vitro.

Authors:  Zhanding Cui; Dengliang Li; Yinli Xie; Kai Wang; Ying Zhang; Guohua Li; Qian Zhang; Xiaoxueying Chen; Yue Teng; Shihui Zhao; Jiang Shao; Fan Xingmeng; Yanli Zhao; Dongju Du; Yanbing Guo; Hailong Huang; Hao Dong; Guixue Hu; Shuang Zhang; Yongkun Zhao
Journal:  Antiviral Res       Date:  2020-06-21       Impact factor: 5.970

3.  Successfully Treated Norovirus- and Sapovirus-Associated Diarrhea in Three Renal Transplant Patients.

Authors:  Noha Ghusson; Gustavo Vasquez
Journal:  Case Rep Infect Dis       Date:  2018-11-12

4.  Potential Therapeutic Agents for Feline Calicivirus Infection.

Authors:  Tulio M Fumian; Daniel Enosi Tuipulotu; Natalie E Netzler; Jennifer H Lun; Alice G Russo; Grace J H Yan; Peter A White
Journal:  Viruses       Date:  2018-08-16       Impact factor: 5.048

Review 5.  Norovirus antivirals: Where are we now?

Authors:  Natalie E Netzler; Daniel Enosi Tuipulotu; Peter A White
Journal:  Med Res Rev       Date:  2018-12-25       Impact factor: 12.944

6.  Amixicile Reduces Severity of Cryptosporidiosis but Does Not Have In Vitro Activity against Cryptosporidium.

Authors:  Luther A Bartelt; David T Bolick; Glynis L Kolling; Erin Stebbins; Christopher D Huston; Richard L Guerrant; Paul S Hoffman
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

7.  An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2.

Authors:  Lauren E Walker; Richard FitzGerald; Geoffrey Saunders; Rebecca Lyon; Michael Fisher; Karen Martin; Izabela Eberhart; Christie Woods; Sean Ewings; Colin Hale; Rajith K R Rajoli; Laura Else; Sujan Dilly-Penchala; Alieu Amara; David G Lalloo; Michael Jacobs; Henry Pertinez; Parys Hatchard; Robert Waugh; Megan Lawrence; Lucy Johnson; Keira Fines; Helen Reynolds; Timothy Rowland; Rebecca Crook; Emmanuel Okenyi; Kelly Byrne; Pavel Mozgunov; Thomas Jaki; Saye Khoo; Andrew Owen; Gareth Griffiths; Thomas E Fletcher
Journal:  Clin Pharmacol Ther       Date:  2021-11-13       Impact factor: 6.903
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.